Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tagrisso save search
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.17%
H: 0.09%
C: -2.76%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 33.84%
H: 1.01%
C: -15.3%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.76%
H: 0.77%
C: 0.0%
reqorsa first lung cancer treat cell expansion therapy study
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
Published: 2023-09-11 (Crawled : 19:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
tagrisso lung cancer trial plus
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.34%
H: 0.21%
C: -2.03%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 1.12%
H: 2.16%
C: -10.76%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.44%
H: 0.03%
C: -1.94%
reqorsa lung approval review cancer cell expansion trial
Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso
Published: 2023-01-24 (Crawled : 14:20) - biospace.com/
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: 0.83%
H: 0.0%
C: -4.78%
test diagnostic tagrisso
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2022-12-14 (Crawled : 19:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -1.61%
H: 1.82%
C: 1.82%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 2.34%
H: 5.98%
C: -0.85%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.76%
H: 1.04%
C: 0.47%
reqorsa lung trial approval review cancer
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
Published: 2022-08-15 (Crawled : 12:20) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -0.09%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 7.91%
H: 13.09%
C: 9.42%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
tagrisso lung trial review cancer phase 1
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial
Published: 2022-08-08 (Crawled : 09:00) - chi-med.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 4.04%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.53%
H: 0.49%
C: -0.85%
tagrisso trial response plus cancer
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting
Published: 2022-07-13 (Crawled : 01:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -2.31%
H: 6.04%
C: 2.9%
tagrisso trial presentation plus results
Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
Published: 2022-06-22 (Crawled : 06:00) - globenewswire.com
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.77%
H: 1.94%
C: 0.99%
tagrisso test diagnostic agreement group
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-02 (Crawled : 14:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.37%
H: 2.02%
C: 2.02%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 3.95%
H: 5.06%
C: -7.17%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
tagrisso gene therapy trial cel lung cancer phase 1 therapy cancer
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published: 2021-11-24 (Crawled : 01:00) - globenewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.02%
H: 1.33%
C: 1.33%
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -4.39%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
orpathys lung cancer china therapy cancer trial
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Published: 2021-09-08 (Crawled : 11:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -2.29%
H: 1.34%
C: 1.29%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -1.85%
H: 0.17%
C: -0.42%
lung cancer china therapy cancer trial
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
Published: 2021-06-23 (Crawled : 18:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 5.45%
H: 11.78%
C: 6.9%
fda lung cancer phase 1 gene therapy therapy cancer trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.